Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
- BIOLOGICAL: Alemtuzumab 12 mg
- BIOLOGICAL: Alemtuzumab 24 mg
- BIOLOGICAL: Interferon beta-1a
Sponsor
Genzyme, a Sanofi Company
Collaborators